Key result
The ESC-PCI Guidelines Task Force defends the recommendation for a routine invasive strategy after thrombolysis in STEMI patients based on evidence from randomized trials.
Answers are grounded in this paper and cite their sources.
The ESC-PCI Guidelines Task Force reaffirms their recommendation for a routine invasive strategy after thrombolysis in STEMI patients based on randomized trial evidence.
The members of the ESC-PCI Guidelines Task Force1 greatly appreciate the thoughtful comments by Dr Dieker et al. and Dr Kholeif. We are pleased that Dr Dieker agrees with us regarding the comparison between primary PCI and thrombolysis. We also agree that we have to wait for ASSENT-IV, OAT, and APRICOT-3 for further insights into the changing field of optimal STEMI treatment. However, regarding a ‘selective’ invasive strategy, i.e. in the case of recurrent ischaemia and/or haemodynamic instability, we do not think we differ with the last year's AHA/ACC STEMI guidelines2 because we still recommend this strategy at evidence level IB (Table 7, p. 8171). Our alternative recommendation of a routine coronary angiography after thrombolysis and PCI, if applicable, is not primarily based on ‘observational data from registries and subgroup analyses’ but rather on four randomized trials (Table 6, p. 8171). At this point, it is important to emphasize that we followed a general consensus demanding randomized trials with a primary clinical endpoint, adequately powered and reaching its primary endpoint to obtain levels of evidence A or B. As there are two randomized trials (SIAM-III and GRACIA-1) with a primary clinical endpoint adequately powered and with positive results comparing the benefit of early post-thrombolysis PCI vs. a conservative strategy, the level of evidence resulted in an ‘A’. For the ‘elective’ strategy of pre-discharge inducible ischaemia in patients with STEMI after thrombolysis, there is only a single randomized study (DANAMI-1), thus resulting in a level B. The critique of ‘clustering’ the four studies in Table 6 with a total of 1031 patients is well taken. However, Dr Dieker might consider that DANAMI-1 randomized 1008 patients, a number similar to the one he criticized. Predominantly, on the basis of GRACIA-1, we strongly believe that a routine invasive strategy after thrombolysis implementation in daily clinical practice comes at an adequate point in time and not too early as Dr Dieker suggests.
No takes yet. Share an insight, caveat, or question.
Sigmund Silber (2005) conducted a letter in STEMI. The ESC-PCI Guidelines Task Force defends the recommendation for a routine invasive strategy after thrombolysis in STEMI patients based on evidence from randomized trials.
Synapse has enriched 10 related papers. Consider them for comparative context: